Wedmont Private Capital Has $2.16 Million Stock Position in Abbott Laboratories $ABT

Wedmont Private Capital trimmed its stake in Abbott Laboratories (NYSE:ABT) by 17.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,000 shares of the healthcare product maker’s stock after selling 4,899 shares during the quarter. Wedmont Private Capital’s holdings in Abbott Laboratories were worth $2,160,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. MidAtlantic Capital Management Inc. acquired a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $25,000. Cornerstone Financial Management LLC acquired a new position in Abbott Laboratories in the fourth quarter worth approximately $25,000. Purpose Unlimited Inc. bought a new position in Abbott Laboratories during the fourth quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in Abbott Laboratories in the fourth quarter valued at approximately $26,000. Finally, Abound Financial LLC bought a new stake in Abbott Laboratories in the fourth quarter worth approximately $26,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on ABT. The Goldman Sachs Group reduced their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. UBS Group decreased their target price on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. JPMorgan Chase & Co. increased their price target on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Weiss Ratings upgraded shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. Finally, BTIG Research upped their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $119.50.

Abbott Laboratories Price Performance

NYSE:ABT opened at $108.29 on Tuesday. The firm has a market cap of $187.38 billion, a PE ratio of 35.05, a price-to-earnings-growth ratio of 2.01 and a beta of 0.59. The company’s 50-day moving average price is $104.74 and its two-hundred day moving average price is $100.00. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter last year, the business earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.